These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 15364158

  • 1. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients.
    Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E.
    Diabetes Res Clin Pract; 2004 Oct; 66(1):23-9. PubMed ID: 15364158
    [Abstract] [Full Text] [Related]

  • 2. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ.
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [Abstract] [Full Text] [Related]

  • 3. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
    Dashora U, Ashwell SG, Home PD.
    Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
    [Abstract] [Full Text] [Related]

  • 4. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 5. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A.
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [Abstract] [Full Text] [Related]

  • 6. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J.
    J Diabetes Complications; 2007 Oct; 21(1):20-7. PubMed ID: 17189870
    [Abstract] [Full Text] [Related]

  • 7. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.
    Gredal C, Rosenfalck A, Dejgaard A, Hilsted J.
    Diabetes Res Clin Pract; 2008 May; 80(2):293-8. PubMed ID: 18304675
    [Abstract] [Full Text] [Related]

  • 8. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
    Schwartz S, Zagar AJ, Althouse SK, Pinaire JA, Holcombe JH.
    Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
    [Abstract] [Full Text] [Related]

  • 9. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 10. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W, Ji Q, Zhu D, Yang J, Chen L, Liu Z, Yu D, Yan L.
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [Abstract] [Full Text] [Related]

  • 11. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H, Kothare PA, Skrivanek Z, de la Peña A, Atkins M, Ernest CS, Trautmann ME.
    Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes.
    Danne T, Råstam J, Odendahl R, Näke A, Schimmel U, Szczepanski R, Moeller J, Deiss D.
    Pediatr Diabetes; 2007 Oct; 8(5):278-85. PubMed ID: 17850471
    [Abstract] [Full Text] [Related]

  • 14. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study.
    Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P.
    Diabetes Metab Res Rev; 2004 Oct; 20(6):472-8. PubMed ID: 15386822
    [Abstract] [Full Text] [Related]

  • 15. Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes.
    Forst T, Eriksson JW, Strotmann HJ, Bai S, Brunelle R, Gulliya KS, Gack S, Gudat U.
    Exp Clin Endocrinol Diabetes; 2003 Apr; 111(2):97-103. PubMed ID: 12746761
    [Abstract] [Full Text] [Related]

  • 16. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients.
    Pala L, Mannucci E, Dicembrini I, Rotella CM.
    Diabetes Res Clin Pract; 2007 Oct; 78(1):132-5. PubMed ID: 17445933
    [Abstract] [Full Text] [Related]

  • 17. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI, Lindström T, Eson Jennersjö P, Paulsson JF, Westermark GT, Olsson AG, Arnqvist HJ.
    Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of acarbose for eliminating the interval between meal consumption and insulin injection in patients with Type 1 diabetes.
    Koch HH, Wudy A, Eberlein G, Quast C.
    Diabetes Nutr Metab; 1999 Jun; 12(3):195-201. PubMed ID: 10554902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.